Off‐label use of sodium glucose co‐transporter inhibitors among adults in type 1 diabetes exchange registry

Real‐world data of 12‐month adjunct sodium‐glucose co‐transporter‐2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis

“…While this may indicate that the risk of DKA as a side effect of SGLT2i therapy in T1D may be overestimated in daily clinical practice, the overall low DKA rate in this patient population may also reflect a highly restrictive patient selection for this treatment or an intense surveillance of patients during the course of the treatment. This is somewhat different to the observations of the T1DX trial, 9 in which participants with SGLT2i therapy experienced a minimal nonsignificant increase in DKA, but unexpectedly, also a higher rate of severe hypoglycaemia.…”

“…Similar results were recently observed in a trial within the US type 1 diabetes exchange registry (T1DX) in adults. 9 There, SGLTi use was also rare and reported by less than 3% of adults. Compared with non-users, those who used SGLTis were more probably of an older age, with a longer diabetes duration, of white race, had private insurance, the use of an insulin pump or continuous glucose monitor, T A B L E 1 Characteristics of patients with type 1 diabetes selected for SGLT2i therapy versus no SGLT2i Note: Data are shown as adjusted means or percentages and 95% confidence interval.…”

Effects of the SGLT2 Inhibition on Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats, a Model of Type 1 Diabetes Mellitus

“…Most studies have evaluated the effect of SGLT2 inhibitors on Type 2 DM but few have assessed their effects on Type 1 DM [14][15][16][17][18][19]; also, their effects on cardiovascular diseases are still unclear in Type 1 DM in both clinical and experimental scenarios. In Type 1 DM, the main mechanism responsible for cardiomyopathy is related to the decreased insulin signaling [20].…”

“…Most studies have evaluated the effect of SGLT2 inhibitors on Type 2 DM, but few have assessed their effects on Type 1 DM [14][15][16][17][18][19]; also, their effects on cardiovascular diseases are still unclear in Type 1 DM in both clinical and experimental scenarios. In this study we evaluated the effects of SGLT2 inhibitor dapagliflozin on cardiac remodeling in rats with streptozotocin-induced diabetes, an experimental model of Type 1 diabetes mellitus.…”

Sodium‐glucose co‐transporter‐2 inhibitors for type 1 diabetes: Not any more?

“…We argue that, for the good of individuals with type 1 diabetes, dapagliflozin should still be indicated for use in this population, as there are no scientific grounds upon which to change the status quo. Over 2 years of experience with dapagliflozin use in type 1 diabetes has shown the overall safety of this therapy, 10 and this safety has been greatly helped by the fact that diabetes healthcare providers themselves have taken the responsibility to provide careful instructions and recommendations for the safe use of dapagliflozin in type 1 diabetes. 11 The benefits of SGLT-2 inhibitor use in type 1 diabetes have recently been confirmed with real-world data.…”